Guggenheim Downgrades Alumis Following Mid-Stage Trial Setback
Guggenheim has downgraded Alumis (ALMS) from Buy to Neutral following a setback in the company's mid-stage trial for its lead drug candidate, envudeucitinib. The Phase 2b LUMUS study failed to meet expectations for treating systemic lupus erythematosus, an autoimmune disorder that affects multiple organs. The downgrade reflects concerns over Alumis' ability to advance its pipeline and deliver on therapeutic promises in the autoimmune disease space. Analysts are now cautious about near-term progress while evaluating long-term potential based on future trial data or strategic developments.
Tickers: $ALMS
Topics: Clinical Trials Pharma Stock Downgrades